A high-quality, recurring-revenue hospital infrastructure leader whose upside hinges on FDA remediation clearing and margin expansion—while tariffs, FX and China pricing pressure test the recovery.
Overview
Getinge AB is a global medical technology leader supplying mission-critical equipment and digital/workflow solutions to operating rooms, ICUs, and life science production environments across 135+ countries with ~12,000 employees and ~30,000 customer institutions. The company operates through three segments—Acute Care Therapies, Surgical Workflows, and Life Science—and is increasingly repositioning its revenue model away from cyclical capital equipment toward more stable, higher-margin recurring revenue from consumables and multi-year service agreements. Recurring revenue is now ~66% of net sales, supported by a large installed base in ventilation, extracorporeal life support (ECLS), and sterile reprocessing. Geographically, sales are diversified (Americas ~41%, EMEA ~36%, APAC ~23%). Hospitals represent the majority of demand (~85% of sales), with the remainder from pharma/biotech and research customers served by the Life Science division. The core value proposition combines engineering reliability, vertically integrated “Total Room” solutions, and a large service organization (~1,500 technicians), creating high switching costs and long-term customer retention.